- $59.93m
- $3.23m
- $31.06m
- 55
- 40
- 36
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.85 | ||
| Price to Tang. Book | 0.85 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.52 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.54% | ||
| Return on Equity | -26.02% | ||
| Operating Margin | -51.29% | ||
Financial Summary
| Year End 31st Jul | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 81.17 | 76.02 | 117.73 | 32.64 | 31.06 | n/a | n/a | -21.01% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.
Directors
- Elazar Rabbani CHM (78)
- Barry Weiner PRE (71)
- Hamid Erfanian CEO (52)
- David Bench CFO (48)
- Kara Cannon OTH (53)
- Dieter Schapfel OTH (58)
- Mary Tagliaferri LED (54)
- Bradley Radoff IND (48)
- Ian Walters IND (53)
- Last Annual
- July 31st, 2023
- Last Interim
- January 31st, 2024
- Incorporated
- August 13th, 1976
- Public Since
- June 13th, 1980
- No. of Shareholders
- 720
- No. of Employees
- 179
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 51,225,734
- Address
- 60 EXECUTIVE BLVD, FARMINGDALE, 11735
- Web
- https://www.enzo.com/
- Phone
- +1 5167555500
- Auditors
- EisnerAmper LLP
Upcoming Events for ENZ
Similar to ENZ
ADC Therapeutics SA
New York Stock Exchange
Alto Neuroscience
New York Stock Exchange
Annovis Bio
New York Stock Exchange
Arcus Biosciences
New York Stock Exchange
Biohaven
New York Stock Exchange
FAQ
What is the Enzo Biochem share price?
As of Today at 19:07 UTC, shares in Enzo Biochem are trading at $1.17. This share price information is delayed by 15 minutes.
How has the Enzo Biochem share price performed this year?
Shares in Enzo Biochem last closed at $1.17 and the price had moved by -55.17% over the past 365 days. In terms of relative price strength the Enzo Biochem share price has underperformed the S&P500 Index by -63.8% over the past year.
What are the analyst and broker recommendations for Enzo Biochem?
The overall consensus recommendation for Enzo Biochem is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Enzo Biochem dividend yield?
Enzo Biochem does not currently pay a dividend.
Does Enzo Biochem pay a dividend?
Enzo Biochem does not currently pay a dividend.
When does Enzo Biochem next pay dividends?
Enzo Biochem does not currently pay a dividend.
How do I buy Enzo Biochem shares?
To buy shares in Enzo Biochem you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Enzo Biochem?
As of the previous close price of $1.17, shares in Enzo Biochem had a market capitalisation of $59.93m.
Where are Enzo Biochem shares listed?
Here are the trading details for Enzo Biochem:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ENZ
What kind of share is Enzo Biochem?
Based on an overall assessment of its quality, value and momentum Enzo Biochem is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Enzo Biochem share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Enzo Biochem share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Enzo Biochem. Over the past six months, its share price has underperformed the S&P500 Index by -30.16%.
As of the last closing price of $1.17, shares in Enzo Biochem were trading -15.5% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Enzo Biochem PE Ratio?
The Enzo Biochem PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Enzo Biochem?
Enzo Biochem's management team is headed by:
- Elazar Rabbani - CHM
- Barry Weiner - PRE
- Hamid Erfanian - CEO
- David Bench - CFO
- Kara Cannon - OTH
- Dieter Schapfel - OTH
- Mary Tagliaferri - LED
- Bradley Radoff - IND
- Ian Walters - IND